Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This study reported that new drugs, despite lower specificity compared to certain immunobiological therapies, are effective across various challenging dermatological diseases, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo.

This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.

This study suggests that particulate matter can induce inflammation in human outer root sheath cells, potentially affecting hair growth, through oxidative stress-dependent MAPK and JAK-STAT signaling pathways.

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This research found that kaempferol, a flavonoid from hair growth-promoting plants, significantly enhanced human dermal papilla cell proliferation and inhibited specific signaling pathways, outperforming minoxidil, with topical application in mice promoting hair growth and thickness, indicating potential as a natural hair loss treatment.

This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.

This study found that H-Ras activation in aged mouse skin leads to increased dysplasia and progression to in situ squamous cell carcinoma, highlighting an age-linked connection between immune changes, senescence, and cancer risk.

This study found that AP-2α and AP-2β transcription factors are crucial for maintaining adult skin homeostasis, with their inactivation in keratinocytes leading to impaired differentiation, hair abnormalities, and inflammation, highlighting their key regulatory roles.

In this study, the wood essential oil of *Juniperus morrisonicola* exhibited significant anti-inflammatory activity, notably inhibiting nitric oxide production in stimulated macrophages, and showed cytotoxic effects against liver cancer cells, suggesting its potential for drug development and eco-friendly applications.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

This review discusses the heterogeneity of Tregs in normal and tumor environments, emphasizing the complexity of targeting tumor-resident Tregs while maintaining systemic immune tolerance, but reports no new findings.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study suggests that cedrol may improve mitochondrial function, gut microbiota, and intestinal barrier integrity, indicating its potential value in treating inflammatory bowel disease.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.